logo Helse Stavanger HF

Research Group Cancer and Medical Physics

Clinical studies

Clinical trials, or experimental treatments, are studies that are conducted on humans to investigate the effects of drugs or other treatment methods, but also to investigate how drugs are converted in the body and whether the side effects are acceptable.

Oncology

Here you will find information about clinical trials in oncology at the Department of Blood and Cancer Diseases that are open for participation.

Breast cancer

  • REBECCA -  an EU project that include 3 clinical studies with the aim to improve the quality of life of breast cancer patients suffering from cancer-related fatigue during and after treatment, by collection of real-world data from a smartwatch and a REBECCA mobil app.  
  • ALICE - Treatment with Atezolizumab or placebo in combination with immunogenic chemotherapy for patients with metastatic triple-negative breast cancer
  • ICON 209-9FN - Treatment with chemotherapy compared to chemotherapy in combination with immunotherapy with Nivolumab and Ipilimumab in patients with luminal B (PAM test) metastatic disease that is hormone positive and Her2 negative
  • OPTIMA - Comparison of standard treatment with choice of treatment based on an extended molecular profile analysis (Prosigna test) for patients with breast cancer and lymph node involvement.

Cancer of the urinary tract

  • Javelin/B9991001 – Treatment with Avelumab and good follow-up compared to good follow-up alone in patients with metastatic urothelial cancer who have not progressed after 1st line treatment with a platinum regimen.

Malignant melanoma

  • PRODAT - An observational study collecting data on treatment efficacy, dosage and adverse reactions. Applies to patients with advanced malignant melanoma (malignant skin cancer) receiving treatment with Dabrafenib and Trametinib

Gynecological cancer

  • AVANOVA - Treatment with Nirapenib and Bevacizumab compared to niraparib alone in recurrence of ovarian or peritoneal cancer more than 6 months after the last treatment ended.

Bone marrow cancer (myelomatose)

  • C16029 - Ixazomib and dexamethasone vs pomalidimide and dexamethasone in patients with relapse and disease refractory to lenalidomide.
  • IRd/NMSG 23/15 Ixazomib, lenalidomide and dexamethasone both as induction therapy before HDT and consolidation therapy after HDT. Maintenance treatment with either ixazomib and lenalidomide or lenalidomide.
  • Magnolia NMSG 22/14 - Zometa treatment in multiple myeloma. Randomisation after 2 years of treatment to treatment prolonged zometaspanic treatment to 4 years or observation.

Chronic myeloid leukemia

  • DASTOP2 - Patients who have CML and are being treated with tyrosine kinase inhibitors after they have had a recurrence of the disease after stopping treatment once before. Treatment with dasatinib for 2 years prior to stop attempt no. 2.

Acute lymphoblastic leukemia

  • NOPHO ALL 2008 - Treatment protocol for children and adults 18 - 45 years and with some changes for adults up to 65 years. Norwegian Protocol for the Elderly for those > 65 years.

Immunological thrombocytopenia

  • PROLONG - Inclusion in case of non-response to prednisolone. Randomised between Rituximab or Rituximab and dexamethasone. Rituximab maintenance treatment / placebo

Lymphomer

  • SAKK 35/14 - Treatment of patients with follicular lymphoma with Rituximab + Ibrutinib/placebo
  • BIO-CHIC/NLG-LBC-06 - Patients from 18-65 years of age with high-risk diffuse large B-cell lymphoma. After treatment cycle 3, treatment is differentiated on the basis of biological risk factors.
  • Diffuse large B-cell lymphoma Registry study of diffuse large B-cell lymphoma at SUS 2008-2014

Chronic cold agglutinin disease

  • CAD6 - Registration study of patients with chronic cold agglutinin disease (CAD) (PI: S. Berentsen, local PI: Einar Haukås).

Members

Daniel Cacic

Einar Haukås

Peter Albert Meyer

Karita Lenita Falck Moore

Majeed Mohammed Waleed

Health research

Research projects

PhD project

Title: Improving the quality and safety of cancer care: a study of next-of-kin involvement.
PhD candidate: Inger Johanne Bergerød SUH
PhD program in Healthcare and Medicine, Faculty of Health Sciences, UiS
Main Supervisior: Siri Wiig, SHARE, UIS
Co-supervisors: Geir Sverre Braut, SUH/UIS/Stord/Haugesund University College and Bjørnar Gilje, SUH
Start year: 2015 Expected year of submission: 2021
Funded by Stavanger University Hospital (SUH)

The aim of this study is to explore the influence of next-of-kin involvement on quality and safety improvement within cancer care in hospitals. This study also explore how managers and healthcare professionals understand the role of next-of-kin in cancer care, and what methods they use for next-of-kin involvement. The study design is a comparative multiple embedded case study of cancer departments in two Norwegian hospitals.

Planned PhD project with a candidate

Title: Eksperts on own disease? A qualitative study on colorectal patients involvement in treatment, care and educational programs.
PhD candidate: Gry Wallgren, SUH
Main supervisor: Britt Sætre Hansen, SUH/UiS
Co-supervisor: Bjørnar Gilje, SUH

The overall aim of this PhD study is to explore the patient experiences of involvement within education and information during cancer treatment. More specifically, the aim is to increase knowledge about how the experiences by patients with colorectal cancer can improve the quality of existing education and information strategies.

PALLION: Palliative care integrated in oncology

PALLION is a multi-center cluster-randomized study where the aim is to investigate the patient benefit of closer and earlier integration of palliative care and treatment. Our department has been randomized to the intervention arm, in which patients are offered a systematic program of symptom registration and personalized follow-up by oncologists with a special training.

The main organizers of the project is Jon Håvard Loge and Stein Kaasa at Oslo University Hospital. Local responsible is Herish Garressori.

Publications

Bergerød, I.J., Gilje, B., Braut, G.S., & Wiig, S. (2018) Next-of-kin involvement in improving hospital cancer care quality and safety – a qualitative cross-case study as basis for theory development. BMC Health Service Research,18 (1), 324.doi:10.1186/s12913-018-3141-7

Bergerød, I.J., Gilje, B; Braut, G.S. & Wiig, S. (2018) Resilience From a Stakeholder Perspective: The Role of Next-of-Kin in Cancer Care, J Patient Saf.doi:10.1097/pts.0000000000000532

Bergerød,I.J., Dalen, I., Gilje, B., Braut, G.S & Wiig, S. Measuring next of kin satisfaction with cancer care as basis for improving quality and patient safety in hospitals (ongoing)

Aunan, S.T.; Wallgren, G.C., & Hansen, B.S. (2018) Breast cancer surviors` experiences of dealing with information during- and after adjuvant treatment: A qualitative study, Journal of clinical nursing. Doi:10.1111/jocn.14700

Members

Inger Johanne Bergerød, Oncology nurse, MSc, doctoralstudent
Gry Wallgren, Oncology nurse, MSc

Partners

Locally

Haukeland University Hospital
University of Stavanger, Faculty of health sciences
Lærings- og mestringssenteret ved SUS
Vardesenteret i Stavanger
Pårørendesenteret i Stavanger

National

Nasjonalt senter for læring og utvikling (Læringssenteret)
Carer research network
Oslo University Hospital

International

SHARE center for Resilience in Healthcare, University of Stavanger

​

Last updated 3/1/2024